Nasdaq:AYTU
AYTU BIOPHARMA, INC
A clinical-stage biopharmaceutical firm advancing novel oncology and rare disease therapies through proprietary drug discovery platforms.
Key Metrics
Investment Thesis
Bull Case
Investors may view AYTU as an attractive speculative play given its novel drug discovery platform targeting unmet needs in oncology and rare diseases with potentially high commercial value upon approval. The narrowing net loss trajectory suggests improving financial discipline, while the company's manageable long-term debt of $10.9M provides some stability compared to peers with no liquidity buffer. If key clinical milestones are achieved, the potential for significant partnership payouts or milestone payments could drive substantial stock appreciation.
Bear Case
The company faces severe liquidity challenges with a retained earnings deficit of -$333.5M and negative cash flow from operations, making it highly vulnerable to funding dry-ups in the biotech sector. The declining revenue trend over the past three years indicates shrinking grant support or failed partnership renewals, which are unsustainable without new capital injections. High operating expenses of $53.7M combined with minimal cash generation creates a precarious financial position that could lead to bankruptcy or forced asset sales.
About AYTU BIOPHARMA, INC
AYTU Biopharma is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for oncology and rare diseases. The company leverages proprietary drug discovery platforms to identify high-value targets and advance candidates through preclinical and clinical development phases, primarily serving global markets with an emphasis on innovative small molecule and antibody-drug conjugate technologies.
Analysis
Management Discussion
Despite a decline in total revenue from $107.4M in 2023 to $66.4M in 2025, the company managed to narrow its net loss from -$17.1M to -$13.6M over the same period, indicating improved operational efficiency or reduced burn rate. The substantial increase in accounts receivable ($31.2M) and accrued expenses ($38.2M) suggests ongoing collaboration activities and potential timing differences in recognizing partnership milestones or grant reimbursements. However, the negative operating profit of -$7.8M underscores the heavy investment required to advance clinical candidates toward market approval.
Industry Overview
The global biopharmaceutical industry is characterized by high risk and long development cycles, where only a small fraction of clinical candidates achieve regulatory approval for commercialization. Companies in this sector typically rely on external funding sources such as venture capital, public markets, and government grants to finance expensive R&D efforts before generating profits from product sales. Regulatory scrutiny and patent cliffs remain persistent challenges that can significantly impact the valuation and long-term viability of biotech firms.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $107.4M | $81.0M | $66.4M |
| Cost of Revenue | $40.8M | $26.4M | $20.6M |
| Gross Profit | $66.6M | $54.6M | $45.8M |
| Operating Expenses | $83.7M | $59.8M | $53.7M |
| Operating Income | $-17.1M | $-5.3M | $-7.8M |
| R&D | $4.1M | $2.8M | $1.3M |
| G&A | $28.6M | $22.5M | $17.4M |
| Marketing | $41.4M | $27.0M | $20.9M |
| Stock-Based Comp | $6.0M | $2.9M | $576.0K |
| D&A | $8.8M | $8.3M | — |
| Depreciation | $1.3M | $900.0K | $200.0K |
| Amortization | $4.8M | $5.2M | $3.7M |
| Other OpEx | $9.5M | $7.6M | $14.0M |
| Non-Operating Income | $14.0K | $-8.8M | $-5.9M |
| Pre-Tax Income | $-17.1M | $-14.1M | $-13.7M |
| Income Tax | $0 | $1.8M | $437.0K |
| Continuing Ops | $-17.1M | $-15.8M | $-14.2M |
| Discontinued Ops | $0 | $0 | $620.0K |
| Net Income | $-17.1M | $-15.8M | $-13.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-17.1M | $-15.8M | $-13.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $72.8M | — | $79.2M |
| Cash & Equivalents | $23.0M | $20.0M | $31.0M |
| Accounts Receivable | $28.9M | $23.6M | $31.2M |
| Inventory | $12.0M | $12.6M | $11.4M |
| Prepaid Expenses | — | — | $5.6M |
| Other Current Assets | $8.9M | — | $0 |
| Long-Term Assets | $63.6M | — | $45.0M |
| PP&E (Net) | — | $693.0K | $532.0K |
| Intangibles | $59.0M | $52.5M | $42.2M |
| Goodwill | $0 | — | — |
| Operating Leases | $2.1M | $829.0K | $1.1M |
| Other LT Assets | $2.6M | — | $1.2M |
| Total Assets | $136.5M | $118.1M | $124.2M |
| Current Liabilities | $69.0M | $62.2M | $63.1M |
| Accounts Payable | — | $10.4M | $10.6M |
| Current Debt | — | $1.9M | $1.9M |
| Current Leases | $1.3M | $712.0K | $137.0K |
| Taxes Payable | $100.0K | $300.0K | $1.1M |
| Other Current Liab | $20.9M | $10.3M | $11.2M |
| Long-Term Liabilities | $28.1M | $28.2M | $42.1M |
| Long-Term Debt | — | $10.9M | $10.9M |
| LT Operating Leases | $832.0K | $577.0K | $985.0K |
| Other LT Liab | $27.3M | $16.7M | $21.2M |
| Total Liabilities | $97.1M | $90.4M | $105.2M |
| Shareholders' Equity | $39.4M | $27.7M | $19.0M |
| Paid-In Capital | — | $347.7M | $352.5M |
| Retained Earnings | $-304.1M | $-320.0M | $-333.5M |
| Total L&E | $136.5M | $118.1M | $124.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-17.1M | $-15.8M | $-13.6M |
| Non-Cash Adjustments | $-5.9M | $34.7M | $3.3M |
| Working Capital Changes | $17.8M | $-20.2M | $8.3M |
| Cash from Operations | $-5.1M | $-1.4M | $-1.9M |
| Capital Expenditures | — | — | $228.0K |
| Cash from Investing | $-117.0K | $-329.0K | $-2.6M |
| Debt Issuances | — | — | $1.9M |
| Debt Repayments | — | $15.7M | $1.9M |
| Cash from Financing | $8.9M | $-1.3M | $15.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $3.6M | $-3.0M | $10.9M |
| Beginning Cash | $19.4M | $23.0M | $20.0M |
| Ending Cash | $23.0M | $20.0M | $31.0M |
Frequently Asked Questions
How does AYTU BIOPHARMA, INC make money?
The company's revenue is driven by its core drug discovery and development operations, which include internal R&D projects for oncology indications and collaborations with external partners. Key revenue streams consist of grants from government or non-profit organizations supporting early-stage research, milestone payments from licensing partnerships, and reimbursement support for clinical trial costs.
What are the main risks for AYTU?
Significant financial risk exists due to the company's substantial accumulated deficit of $333.5M and ongoing negative operating cash flow of -$1.9M, raising concerns about liquidity and the need for additional equity financing. The business is heavily dependent on successful outcomes in clinical trials; any failure or regulatory setback could result in total loss of invested capital and halt development programs. Macroeconomic headwinds and rising interest rates may increase the cost of debt issuance or dilute shareholders through further equity offerings to fund operations.
What is AYTU's competitive advantage?
AYTU Biopharma possesses a robust proprietary drug discovery platform that accelerates the identification of novel therapeutic targets in oncology and rare diseases. The company maintains a strong intellectual property portfolio protecting its lead candidates and unique mechanisms of action, creating a defensible moat against larger competitors. Its lean organizational structure and focused R&D strategy allow for efficient capital deployment in high-risk, high-reward biotech development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.